Immunotherapy in Oncology: Gaining Momentum

Table of Contents

1 Executive Summary

2 Methodology

3 Table of Contents

• 3.1 List of Boxes
• 3.2 List of Figures
• 3.3 List of Tables

4 Vaccine Strategies: Challenges & Opportunities

5 Key Antibody Developmental Strategies

6 Competitive Landscape in Cancer Vaccines

• 6.1 Countries & Players: Who are In the Lead?
  • 6.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
  • 6.1.2 Approved Cancer Vaccine Drugs: Performance
• 6.2 Deals & Alliances in Cancer Vaccines
  • 6.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
  • 6.2.2 Deals in Prostate Cancer
  • 6.2.3 Deals in Breast Cancer
  • 6.2.4 Deals in Leukemia & Lymphoma
  • 6.2.5 Drug Delivery Deals in Cancer Vaccines
  • 6.2.6 Adjuvant Deals

7 Antibody Deals on the Rise

• 7.1 Antibody Deals in Phase III
  • 7.1.1 Deal Situation: MDX 010
  • 7.1.2 Deal Situation: WX G250
  • 7.1.3 Deal Situation: Zanolimumab
• 7.2 Antibody Deals in Phase II
  • 7.2.1 Deal Situation: Mapatumumab
  • 7.2.2 Deal Situation: GCR 3888
  • 7.2.3 Deal Situation: MDX 070
  • 7.2.4 Deal Situation: CDP 860
  • 7.2.5 Deal Situation: Tru-Scint OV
  • 7.2.6 Deal Situation: SC 1
  • 7.2.7 Deal Situation: PRO 70769
  • 7.2.8 Deal Situation: XR 303
  • 7.2.9 Deal Situation: HumaRAD-HN

8 Tumor Antigens

• 8.1 Tumor Antigens: General Comments
• 8.2 Antigen Discovery
  • 8.2.1 Classical Immunology Approach
  • 8.2.2 The Reverse Immunology Approach
  • 8.2.3 Company Platforms
    • 8.2.3.1 Epitope Identification System - EIS®
    • 8.2.3.2 EPIQUEST system
    • 8.2.3.3 MolecularBreeding™ & MaxyScan™
    • 8.2.3.4 ProtEx™ technology
    • 8.2.3.5 Rapid Identification of Alternative Splicing (RIAS) System
    • 8.2.3.6 SMARTOMICS™
• 8.3 Specific Antigen Processing Technologies Increasing Antigen Presentation

9 Immunomodulators & Adjuvants in Cancer Vaccines

• 9.1 Overview
• 9.2 Cytokines
  • 9.2.1 Vaccines in Combination with Interleukin-2
  • 9.2.2 Tumor Necrosis Factor
  • 9.2.3 Interferons
• 9.3 Adjuvants
• 9.4 Other Immunomodulating Strategies
  • 9.4.1 An Immune Response Modifying Protein
  • 9.4.2 Immunostimulatory DNA
  • 9.4.3 Ex Vivo Stimulated Immune Cells
  • 9.4.4 Fusion Protein Gain Potent Immune Response
  • 9.4.5 Macrophage and Natural Killer Cells Activation
  • 9.4.6 Selective Suppression of the Immune System to An Antigen
  • 9.4.7 TAP Technology

10 Cancer Vaccine Delivery

• 10.1 Viral Delivery
  • 10.1.1 Introduction
  • 10.1.2 Viral Constructs Put into Use
    • 10.1.2.1 Replicon-based RNA and DNA vaccines
      • 10.1.2.1.1 The Alphavaccine Platform System - ArV™
      • 10.1.2.1.2 MVA-BN
    • 10.1.2.2 Retroviruses
      • 10.1.2.2.1 The SDSV-platform
    • 10.1.2.3 Lentivirus
      • 10.1.2.3.1 LentiPak™
      • 10.1.2.3.2 LentiVector™/ pEGASUS™
    • 10.1.2.4 Adenoviruses
      • 10.1.2.4.1 Failed Adenovirus Delivery Platforms
      • 10.1.2.4.2 GVAX
      • 10.1.2.4.3 TNFerade™
      • 10.1.2.4.4 INGN-225
    • 10.1.2.5 Adeno-associated viruses
      • 10.1.2.5.1 Failed AAV Delivery Platforms
      • 10.1.2.5.2 Genzyme Acquires AAV vector Technology
      • 10.1.2.5.3 MediGene's AAV Platform
    • 10.1.2.6 Herpes Simplex Viruses
      • 10.1.2.6.1 DISC-HSV
      • 10.1.2.6.2 ImmunoVEX
    • 10.1.2.7 Poxviruses
      • 10.1.2.7.1 Hi-8™ PrimeBoost™ platform
      • 10.1.2.7.2 PROSTVAC-VF
      • 10.1.2.7.3 Transgene's MVA Platform
      • 10.1.2.7.4 TroVax
    • 10.1.2.8 Other Poxvirus Systems
    • 10.1.2.9 Baculovirus
    • 10.1.2.9.1 Chimeric virus -like particles (CVLPs)
• 10.2 Bacterias
• 10.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
  • 10.3.1 Introduction
  • 10.3.2 Cell Therapy Strategies
    • 10.3.2.1 Processed Tumor Cells
    • 10.3.2.2 Lysed Tumor Cell Line
    • 10.3.2.3 The Dendritic Cell Strategy that Didn't Work Out
    • 10.3.2.4 HSPs
    • 10.3.2.5 Provenge™
    • 10.3.2.6 Dendritophages
    • 10.3.2.7 Cell-targeting Antibodies
    • 10.3.2.8 Increase Dendritic Cell Number
    • 10.3.2.9 DCVax®
    • 10.3.2.10 ACTIVATE™
• 10.4 Synthetic Delivery Systems & Strategies
  • 10.4.1 Introduction
  • 10.4.2 Biotransport™
  • 10.4.3 Biotype®vector
  • 10.4.4 DNAVax Gene Delivery System
  • 10.4.5 FusitAb™
  • 10.4.6 GeneDrug™
  • 10.4.7 Molecular Conjugates
  • 10.4.8 Naked DNA Delivery
  • 10.4.9 PVLP Technology
  • 10.4.10 Sphingosomal Drug Delivery Technology
  • 10.4.11 STEALTH
  • 10.4.12 Failed Liposomal Systems

11 New Approaches in Antibody Delivery and Design - The Next Generation

• 11.1 How to Make Them Smaller and Different?
• 11.2 Biomaterials in Sustained Delivery Applications
  • 11.2.1 Implants
• 11.3 Gene delivery - the Future?
  • 11.3.1 Delivery Vehicles for DNA
  • 11.3.2 Gene Delivery in Commercialization

12 Cancer Vaccines in Development: By Major Indications

• 12.1 General Oncology Overview
• 12.2 Progress Analysis - Melanoma
• 12.3 Progress Analysis - Breast Cancer
• 12.4 Progress Analysis - Prostate Cancer
• 12.5 Progress Analysis - Lung Cancer
• 12.6 Progress Analysis - Colorectal Cancer
• 12.7 Progress Analysis - Cervical Cancer

13 Antibodies in Clinical Development

• 13.1.1 Prostate Cancer Therapeutics
• 13.1.2 Breast Cancer Therapeutics
• 13.1.3 Colorectal Cancer Therapeutics
• 13.1.4 Melanoma Therapeutics
• 13.1.5 Hematological Cancers Therapeutics
• 13.2 Antibodies in Phase III Clinical Development
  • 13.2.1 Progress Analysis: IGN 101
    • 13.2.1.1 Breast Cancer
    • 13.2.1.2 Lung Cancer
    • 13.2.1.3 Colorectal cancer
  • 13.2.2 Progress Analysis: MDX 010
    • 13.2.2.1 Melanoma
    • 13.2.2.2 Breast Cancer
    • 13.2.2.3 Prostate Cancer
    • 13.2.2.4 Kidney Cancer
  • 13.2.3 Progress Analysis: ONYVAX 105
    • 13.2.3.1 Colorectal cancer
    • 13.2.3.2 Other Indications
  • 13.2.4 Progress Analysis: Ovarex
    • 4.1 Ovarian cancer
  • 13.2.5 Progress Analysis: Panitumumab
    • 13.2.5.1 Solid tumors
    • 13.2.5.2 Colorectal cancer
    • 13.2.5.3 Lung Cancer
    • 13.2.5.4 Kidney Cancer
  • 13.2.6 Progress Analysis: RENCAREX
    • .1 Kidney Cancer
  • 13.2.7 Progress Analysis: Nimotuzumab
    • 13.2.7.1 Brain cancer
    • 13.2.7.2 Pancreatic cancer
    • 13.2.7.3 Head and neck cancer
    • 13.2.7.4 Lung Cancer
  • 13.2.8 Progress Analysis: TransMID
    • .8.1 Brain Cancer
  • 13.2.9 Progress Analysis: Lintuzumab
    • 13.2.9.1 Leukemia
  • 13.2.10 Progress Analysis: Zanolimumab
    • 13.2.10.1 Lymphoma
• 13.3 Antibodies in Phase II Clinical Development
  • 13.3.1 Progress Analysis: ABT-510
    • 13.3.1.1 Kidney Cancer
    • 13.3.1.2 Soft Tissue Sarcoma
    • 13.3.1.3 Lung Cancer
  • 13.3.2 Progress Analysis: BB 10901
    • 13.3.2.1 Lung Cancer
    • 13.3.2.2 Multiple Myeloma
  • 13.3.3 Progress Analysis: CP 675206
    • 13.3.3.1 Melanoma
  • 13.3.4 Progress Analysis: CNTO-328
    • 13.3.4.1 Kidney Cancer
    • 13.3.4.2 Multiple Myeloma
    • 13.3.4.3 Prostate cancer
  • 13.3.5 Progress Analysis: Ecromeximab
    • 13.3.5.1 Melanoma
  • 13.3.6 Progress Analysis: EMD 273063
    • 13.3.6.1 Melanoma
  • 13.3.7 Progress Analysis: WX-G250RIT
    • 13.3.7.1 Billary Cancer
    • 13.3.7.2 Kidney Cancer
  • 13.3.8 Progress Analysis: HGS-ETR1
    • 13.3.8.1 Lung Cancer
    • 13.3.8.2 Lymphoma
    • 13.3.8.3 Colorectal Cancer
    • 13.3.8.4 HGS-ETR2
  • 13.3.9 Progress Analysis: HuMax-CD20
    • 3.3.9.1 Lymphoma
  • 13.3.10 Progress Analysis: HuMax-EGFr
    • 13.3.10.1 Head and Neck Cancer
  • 13.3.11 Progress Analysis: Galiximab
    • 13.3.11.1 Lymphoma
  • 13.3.12 Progress Analysis: PROXINIUM
    • 13.3.12.1 Head and Neck Cancer
    • 13.3.12.2 Bladder Cancer
  • 13.3.13 Progress Analysis: RAV12
    • 13.3.13.1 Colorectal Cancer
  • 13.3.14 Progress Analysis: SGN-15
    • 13.3.14.1 Lung Cancer
    • 13.3.14.2 Prostate Cancer
    • 13.3.14.3 Metastatic Breast and Colorectal Cancer
  • 13.3.15 Progress Analysis: SGN-30
    • 13.3.15.1 Lymphoma
  • 13.3.16 Progression Analysis: VEGF-Trap
    • 13.3.16.1 Solid Tumors
  • 13.3.17 Progress Analysis: MEDI 522
    • 13.3.17.1 Colorectal Cancer
    • 13.3.17.2 Melanoma
  • 13.3.18 Progress Analysis: Volociximab
    • 13.3.18.1 Kidney Cancer

14 Disclaimer

• 14.1 Liability
• 14.2 Completeness

15 Drug Index

16 Company Index